Author: Aptevo Therapeutics

Posted Date:

March 26, 2026

Aptevo Provides State of the Business Report and 2025 Financial Results

Aptevo Therapeutics

March 26, 2026
Aptevo to Participate in March 2026 Conferences

Aptevo Therapeutics

March 19, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Aptevo Therapeutics

March 10, 2026
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics

February 3, 2026